Literature DB >> 19616518

Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.

Jenelle L Dorner1, Benjamin R Miller, Emma L Klein, Alexander Murphy-Nakhnikian, Rachel L Andrews, Scott J Barton, George V Rebec.   

Abstract

A behavior-related deficit in the release of ascorbate (AA), an antioxidant vitamin, occurs in the striatum of R6/2 mice expressing the human mutation for Huntington's disease (HD), a dominantly inherited condition characterized by striatal dysfunction. To determine the role of corticostriatal fibers in AA release, we combined slow-scan voltammetry with electrical stimulation of cortical afferents to measure evoked fluctuations in extracellular AA in wild-type (WT) and R6/2 striatum. Although cortical stimulation evoked a rapid increase in AA release in both groups, the R6/2 response had a significantly shorter duration and smaller magnitude than WT. To determine if corticostriatal dysfunction also underlies the behavior-related AA deficit in R6/2s, we measured striatal AA release in separate groups of mice treated with d-amphetamine (5 mg/kg), a psychomotor stimulant known to release AA from corticostriatal terminals independently of dopamine. Relative to WT, both AA release and behavioral activation were diminished in R6/2 mice. Collectively, our results show that the corticostriatal pathway is directly involved in AA release and that this system is dysfunctional in HD. Moreover, because AA release requires glutamate uptake, a failure of striatal AA release in HD is consistent with an overactive glutamate system and diminished glutamate transport, both of which are thought to be central to HD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616518      PMCID: PMC2745264          DOI: 10.1016/j.brainres.2009.07.019

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  60 in total

1.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

2.  Impaired glutamate uptake in the R6 Huntington's disease transgenic mice.

Authors:  J C Liévens; B Woodman; A Mahal; O Spasic-Boscovic; D Samuel; L Kerkerian-Le Goff; G P Bates
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

3.  Dynamic changes in extracellular fluid ascorbic acid monitored by in vivo electrochemistry.

Authors:  B Ghasemzadeh; J Cammack; R N Adams; B Ghasemzedah
Journal:  Brain Res       Date:  1991-04-26       Impact factor: 3.252

Review 4.  Oxidative damage in Huntington's disease pathogenesis.

Authors:  Susan E Browne; M Flint Beal
Journal:  Antioxid Redox Signal       Date:  2006 Nov-Dec       Impact factor: 8.401

5.  Ascorbate transport by primary cultured neurons and its role in neuronal function and protection against excitotoxicity.

Authors:  Shenfeng Qiu; Liying Li; Edwin J Weeber; James M May
Journal:  J Neurosci Res       Date:  2007-04       Impact factor: 4.164

6.  Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.

Authors:  Jenelle L Dorner; Benjamin R Miller; Scott J Barton; Tyler J Brock; George V Rebec
Journal:  Behav Brain Res       Date:  2007-01-18       Impact factor: 3.332

7.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

8.  Unilateral neostriatal kainate, but not 6-OHDA, lesions block dopamine agonist-induced ascorbate release in the neostriatum of freely moving rats.

Authors:  R C Pierce; D W Miller; D B Reising; G V Rebec
Journal:  Brain Res       Date:  1992-11-27       Impact factor: 3.252

9.  Antidromically identified striatonigral projection neurons in the chronically implanted behaving rat: relations of cell firing to amphetamine-induced behaviors.

Authors:  L J Ryan; S J Young; D S Segal; P M Groves
Journal:  Behav Neurosci       Date:  1989-02       Impact factor: 1.912

10.  The effect of unilateral cortical lesions on the circadian changes in rat striatal ascorbate and homovanillic acid levels measured in vivo using voltammetry.

Authors:  R D O'Neill; R A Grunewald; M Fillenz; W J Albery
Journal:  Neurosci Lett       Date:  1983-11-21       Impact factor: 3.046

View more
  13 in total

1.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

Review 2.  Corticostriatal network dysfunction in Huntington's disease: Deficits in neural processing, glutamate transport, and ascorbate release.

Authors:  George V Rebec
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

3.  Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.

Authors:  Benjamin Ray Miller; Ilya Bezprozvanny
Journal:  Future Neurol       Date:  2010-09

4.  Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease.

Authors:  Benjamin R Miller; Jenelle L Dorner; Kendra D Bunner; Thomas W Gaither; Emma L Klein; Scott J Barton; George V Rebec
Journal:  J Neurochem       Date:  2012-03-28       Impact factor: 5.372

5.  Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.

Authors:  George V Rebec
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

6.  Dopamine Promotes Ascorbate Release from Retinal Neurons: Role of D1 Receptors and the Exchange Protein Directly Activated by cAMP type 2 (EPAC2).

Authors:  Thaísa Godinho da Encarnação; Camila Cabral Portugal; Caio Eduardo Nogueira; Felipe Nascimento Santiago; Renato Socodato; Roberto Paes-de-Carvalho
Journal:  Mol Neurobiol       Date:  2018-02-23       Impact factor: 5.590

7.  A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice.

Authors:  Aníbal I Acuña; Magdalena Esparza; Carlos Kramm; Felipe A Beltrán; Alejandra V Parra; Carlos Cepeda; Carlos A Toro; René L Vidal; Claudio Hetz; Ilona I Concha; Sebastián Brauchi; Michael S Levine; Maite A Castro
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Behavior modulates effective connectivity between cortex and striatum.

Authors:  Alexander Nakhnikian; George V Rebec; Leslie M Grasse; Lucas L Dwiel; Masanori Shimono; John M Beggs
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

9.  Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.

Authors:  Taneli Heikkinen; Kimmo Lehtimäki; Nina Vartiainen; Jukka Puoliväli; Susan J Hendricks; Jack R Glaser; Amyaouch Bradaia; Kristian Wadel; Chrystelle Touller; Outi Kontkanen; Juha M Yrjänheikki; Bruno Buisson; David Howland; Vahri Beaumont; Ignacio Munoz-Sanjuan; Larry C Park
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior.

Authors:  Dario Besusso; Mirjam Geibel; Dana Kramer; Tomasz Schneider; Valentina Pendolino; Barbara Picconi; Paolo Calabresi; David M Bannerman; Liliana Minichiello
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.